Sprache auswählen
VEGFA
VEGFA Molekülinformation
| Englischer Name | Vascular endothelial growth factor A | Anzahl der inverkehr gebrachten Arzneimittel | 50 |
| Anzahl der klinischen Arzneimittel | 60 | Target-Alias | Vascular Endothelial Growth Factor，VEGF-A，MVCD1，Vascular endothelial growth factor A，VEGF，VEGFA，VPF，Vascular Endothelial Growth Factor A165，Vascular permeability factor，Vascular Endothelial Growth Factor A121 |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Vascular endothelial growth factor A |
| Target-Alias | Vascular Endothelial Growth Factor，VEGF-A，MVCD1，Vascular endothelial growth factor A，VEGF，VEGFA，VPF，Vascular Endothelial Growth Factor A165，Vascular permeability factor，Vascular Endothelial Growth Factor A121 |
| Anzahl der inverkehr gebrachten Arzneimittel | 50 |
| Anzahl der klinischen Arzneimittel | 60 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
VEGFA Produktliste
- Attribut
Kits (1)
- Produktbibliothek
In Forschung (1)
- Spezies
Human (1)
- Etikett
- (1)
- Marker
- (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
FRT-P042 |  Human | - | Human VEGFA / VEGF R1 Inhibitor Screening Kit (TR-FRET) |  Vorbestellung |
Gesamtmenge1
- 1
VEGFA Molekülalias
VEGFA
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Ixoberogene soroparvovec | ADVM-022 | Phase 3 Clinical | Weill Cornell Medical College | Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy | Details |
| Bevacizumab biosimilar(Jiangsu Aosaikang) | ASK-1202; AMD-B; AK-3008; ASK-B1202; ASKB1202 | Phase 3 Clinical | Jiangsu Aosaikang Pharmaceutical Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Ranibizumab biosimilar (Reliance Life Sciences Group) | R-TPR-024 | Phase 3 Clinical | Reliance Life Sciences | Macular Degeneration | Details |
| Tovecimig | ES-104; NOV-1501; CTX-009; HD-B001A; HDB001A; TR-009; ABL001; ABL-001 | Phase 3 Clinical | Abl Bio Inc | Biliary Tract Neoplasms; Solid tumours; Rectal Neoplasms; Colonic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Bile Duct Neoplasms; Ampullary Carcinoma; Gallbladder Neoplasms | Details |
| Bevacizumab biosimilar (Huaota Biopharm/Shanghai Junshi Biosciences) | JS-501; HOT-1010 | Phase 3 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Prestige BioPharma/Hanwha Biologics) | HD-204 | Phase 3 Clinical | Hanwha Biologics | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Aflibercept biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
| Bevacizumab biosimilar (Alphamab/R-Pharm) | RPH-001 | Phase 3 Clinical | Suzhou Alphamab Co Ltd, R-Pharm | Colorectal Neoplasms | Details |
| Bevacizumab biosimilar(Zhejiang Teruisi Pharmaceutical) | TRS-003 | Phase 3 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Ranibizumab biosimilar (Chong Kun Dang Pharmaceutical) | CKD-701 | Phase 3 Clinical | Chong Kun Dang Pharmaceutical Corp | Macular Degeneration | Details |
| Ranibizumab biosimilar (Lupin) | LUBT-010 | Phase 3 Clinical | Lupin Ltd | Macular Degeneration | Details |
| Bevacizumab biosimilar (Genor Biopharma) | GB-222 | Phase 3 Clinical | Genor Biopharma Co Ltd | Brain Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
| Muparfostat sodium | PI-88 | Phase 3 Clinical | Australian National University | Liver Neoplasms; Skin Melanoma; Solid tumours; Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar(Enzene Biosciences) | Phase 3 Clinical | Enzene Biosciences Ltd | Colorectal Neoplasms | Details | |
| Bevacizumab biosimilar (Curateq Biologics) | BP01; BP-01 | Phase 3 Clinical | Colonic Neoplasms | Details | |
| Aflibercept biosimilar (Shilpa Biologicals) | SBDM-03 | Phase 3 Clinical | Shilpa Biologicals Pvt Ltd | Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (Centus Biotherapeutics) | FKB-238 | Phase 3 Clinical | Fujifilm Kyowa Kirin Biologics Co Ltd | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Aflibercept Biosimilar(Rophibio) | RBS-001 | Phase 3 Clinical | Rophibio Inc | Wet Macular Degeneration; Macular Degeneration | Details |
| Bevacizumab biosimilar(Laboratorios Sophia) | PRO-169 | Phase 3 Clinical | Laboratorios Sophia Sa De Cv | Diabetic macular oedema | Details |
| Aflibercept biosimilar (Mabwell) | 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Diabetic macular oedema | Details |
| Bevacizumab biosimilar (Beijing Science Sun/Beijing Lvzhu) | K-11 | Phase 3 Clinical | Beijing Lvzhu Biological Technology Co Ltd, Beijing Science Sun Pharmaceutical Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| PM-8002 | PM8002; PM-8002; BNT-327 | Phase 3 Clinical | Biotheus Inc | Solid tumours; Liver Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Triple Negative Breast Neoplasms; Neuroendocrine Tumors; Mesothelioma; Breast Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Phase 3 Clinical | Sam Chun Dang Pharm Co Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
| Varisacumab | R-84; GNR-011; AT-001-IBCG | Phase 3 Clinical | Peregrine, The University Of Texas Southwestern Medical Center | Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AZD-8601 | mRNA-AZD-8601; AZD-8601 | Phase 2 Clinical | Astrazeneca Plc, Moderna Inc | Heart Failure | Details |
| MP-0250 | MP-0250 | Phase 2 Clinical | Molecular Partners Ag | Neoplasms; Multiple Myeloma; Carcinoma, Non-Small-Cell Lung | Details |
| ALS-L1023 | ALS-L1023 | Phase 2 Clinical | Angiolab Inc | Sleep Bruxism; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Syndrome; Rosacea; Otitis Media with Effusion; Temporomandibular Joint Disorders; Obesity, Abdominal; Macular Degeneration | Details |
| JS-207 | JS-207 | Phase 2 Clinical | Dotbio Pte Ltd | Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Eastern Biotech) | JY-028 | Phase 2 Clinical | Beijing Eastern Biotech Co Ltd | Wet Macular Degeneration; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Macular Degeneration | Details |
| ELGN-EYE | ELGN-EYE | Phase 2 Clinical | Elgan Pharma Ltd | Retinopathy of Prematurity | Details |
| SCT-501(National Cancer Institute) | SCT-501 | Phase 2 Clinical | National Cancer Institute | Kidney Neoplasms | Details |
| Y-400 | Y-400 | Phase 2 Clinical | Wuhan Yzy Biopharma Co Ltd | Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details |
| BI-836880 | BI-836880 | Phase 2 Clinical | Ablynx Nv, C.H. Boehringer Sohn Ag & Co. Kg | Squamous Cell Carcinoma of Head and Neck; Neoplasms; Wet Macular Degeneration; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| SYB-509 | SYB-509 | Phase 1 Clinical | Yuanda Shuyang Life Sciences (Chengdu) Co Ltd | Carcinoma, Transitional Cell; Carcinoma, Hepatocellular | Details |
| Vanucizumab | RG-7221; RO-5520985; B800Z06O8K (UNII code) | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms; Colorectal Neoplasms | Details |
| Bevacizumab biosimilar (North China Pharmaceutical) | MG-021 | Phase 1 Clinical | North China Pharmaceutical Company Ltd | Colorectal Neoplasms; Macular Degeneration; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar(Guilin Sanjin) | Phase 1 Clinical | Guilin Sanjin Pharmaceutical Co Ltd | Macular Degeneration | Details | |
| Ranibizumab biosimilar (CJSC Generium) | GNR-067 | Phase 1 Clinical | Cjsc Generium | Macular Degeneration | Details |
| Bevacizumab biosimilar (Shanghai Kangdai) | Phase 1 Clinical | Shanghai Kanda Bio-Technology Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Bevacizumab biosimilar (JHL Biotech) | JHL-1149 | Phase 1 Clinical | Eden Biologics Inc | Neoplasms | Details |
| Ziv-aflibercept biosimiliar (Boan Biopharma) | LY-01012; BA-1103 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Colorectal Neoplasms | Details |
| Pasireotide long-acting formulation (Camurus) | CAM-4071 | Phase 1 Clinical | Camurus Ab | Endocrine System Diseases | Details |
| Bevacizumab biosimilar (Tanvex BioPharma) | TX-16 | Phase 1 Clinical | Tanvex Biopharma | Colorectal Neoplasms | Details |
| PB-101 | PB-101 | Phase 1 Clinical | Panolos Bioscience Inc | Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
| IBI-333 | IBI-333 | Phase 1 Clinical | Innovent Biologics (Usa), Inc | Wet Macular Degeneration; Macular Degeneration | Details |
| IBI-324 | IBI-324 | Phase 1 Clinical | Innovent Biologics (Usa), Inc | Diabetic macular oedema | Details |
| EB-105 | EB-105 | Phase 1 Clinical | Eluminex Biosciences (Suzhou) Ltd | Diabetic macular oedema; Diabetic Retinopathy | Details |
| Y-332 | Y-332 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd, Wuhan Yzy Medical Science And Technology Co Ltd | Solid tumours | Details |
| Dilpacimab | ABT-165; DVD-Ig ABT-165 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Neoplasms | Details |
| Aflibercept biosimilar(Generium) | GNR-098 | Phase 1 Clinical | Generium Pharmaceuticals | Macular Degeneration | Details |
| CS-2009 | CS-2009 | Phase 1 Clinical | Cstone Pharmaceuticals | Solid tumours; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Gedeon Richter) | Phase 1 Clinical | Gedeon Richter Plc | Neoplasms | Details | |
| HG-202 | HG-202; HG202 | Phase 1 Clinical | HuiGene Therapeutics Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
| Aflibercept biosimilar (Zein Bioteccnology) | Phase 1 Clinical | Zein Bioteccnology Co Ltd | Diabetic macular oedema | Details | |
| BD-311 | BD311 | Phase 1 Clinical | Shanghai BDgene Co Ltd | Diabetic macular oedema; Macular Degeneration; Retinal Vein Occlusion | Details |
| ASKG-712 | ASKG-712; AM-712 | Phase 1 Clinical | Askgene Pharma | Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details |
| OB-318 | OB-318 | Phase 1 Clinical | Oneness Biotech Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
| Bevacizumab biosimilar(Guangdong Dongyangguang) | Phase 1 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
| Colorectal cancer vaccine (Immunovo/Pepscan Therapeutics) | Phase 1 Clinical | Pepscan Systems | Colorectal Neoplasms | Details | |
| Bevacizumab biosimilar(Bioxpress) | BXT-2316 | Clinical | Bioxpress Therapeutics Sa | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Bevacizumab biosimilar (Qilu Pharma) | QL-1101 | Approved | Qilu Pharmaceutical Co Ltd | 安可达 | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Qilu Pharmaceutical Co Ltd | 2019-12-06 | Neoplasms; Colorectal Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Innovent Biologics) | IBI-305; IBI305; IBI 305; CHS-305 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达攸同, BYVASDA, Bevagen | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Innovent Biologics(Suzhou) Co Ltd | 2020-06-17 | Ovarian Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Pfizer) | PF-6439535; PF-06439535 | Approved | Pfizer Inc | Zirabev | EU | Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Pfizer Europe Ma Eeig | 2019-02-14 | Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Elea) | Approved | Laboratorio Elea Phoenix Sa | Lumiere | Argentina | Macular Degeneration | Laboratorio Elea Phoenix Sa | 2018-04-26 | Macular Degeneration | Details | |
| Bevacizumab biosimilar (Samsung Bioepis) | SP-8; SB-8 | Approved | Samsung Bioepis Co Ltd | Aybintio | EU | Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Peritoneal Neoplasms | Samsung Bioepis Nl Bv | 2020-08-19 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Ranibizumab biosimilar (Samsung Bioepis) | AM002; SB-11; SB11 | Approved | Samsung Bioepis Co Ltd | BYOOVIZ | EU | Macular Edema; Diabetic Retinopathy; Wet Macular Degeneration; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetic macular oedema | Samsung Bioepis Nl Bv | 2021-08-18 | Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion; Choroidal Neovascularization | Details |
| Bevacizumab biosimilar (Intas Pharmaceuticals) | INTP-24 | Approved | Intas Biopharmaceuticals | Bevatas | India | Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Glioblastoma; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms | Intas Biopharmaceuticals | 2017-10-04 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Ranibizumab biosimilar (Formycon/Bioeq) | CHS-201; FYB-201 | Approved | Formycon AG, Bioeq Gmbh | CIMERLI, Ranivisio | United States | Macular Edema; Retinal Vein Occlusion; Choroidal Neovascularization; Macular Degeneration; Diabetic Retinopathy; Diabetic macular oedema; Wet Macular Degeneration | Coherus Biosciences Inc | 2022-08-02 | Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Diabetes Complications; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetic Retinopathy; Macular Degeneration | Details |
| Bevacizumab biosimilar (AryoGen Biopharma) | BE1040V | Approved | Aryogen Biopharma | Stivant | Iran | Uterine Cervical Neoplasms; Metastatic breast cancer; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Glioblastoma | Aryogen Biopharma | 2019-06-01 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Shanghai Institute Of Biological Products) | SIBP-04 | Approved | Shanghai Institute of Biological Products Co Ltd | 生唯宁 | Mainland China | Colorectal Neoplasms; Glioblastoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Ovarian Neoplasms | Shanghai Institute of Biological Products Co Ltd | 2025-01-08 | Ovarian Neoplasms; Glioblastoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
| Bevacizumab biosimilar (Zydus Cadila) | Approved | Zydus Cadila | Bryxta | India | Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Colorectal Neoplasms; Glioblastoma; Metastatic breast cancer; Carcinoma, Renal Cell | Zydus Cadila | 2017-01-01 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details | |
| Bevacizumab biosimilar (TOT Biopharm) | TAB-008; TOT-102; TAB008; TOT102 | Approved | Tot Biopharm Co Ltd | 朴欣汀, Pusintin | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Tot Biopharm Co Ltd | 2021-12-01 | Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Bevacizumab | G180CU; RO-4876646; RG-435; NSC-704865; G180CL; R-435; G180DL | Approved | Genentech Inc | 安维汀, Avastin | United States | Colorectal Neoplasms | Genentech Inc | 2004-02-26 | Liver Neoplasms; Infections; Respiratory Tract Infections; Pterygium; Ovarian Neoplasms; Solid tumours; Arteriovenous Malformations; Kidney Neoplasms; Head and Neck Neoplasms; Fibrosarcoma; Leiomyosarcoma; Epistaxis; Telangiectasia, Hereditary Hemorrhagic; Leukemia; HIV Infections; Leukemia, Myelogenous, Chronic; Ependymoma; Skin Melanoma; Meningeal Carcinomatosis; Telangiectasis; Diabetes Mellitus, Type 2; Macular Edema; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Esthesioneuroblastoma, Olfactory; Carcinoid Tumor; Rectal Neoplasms; Carcinoma; Hemangioblastoma; Granuloma, Lethal Midline; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Vaginal Neoplasms; Esophageal Neoplasms; Neoplasms, Glandular and Epithelial; Virus Diseases; Papillomavirus Infections; Neoplasms, Squamous Cell; Respiratory Tract Diseases; Glioblastoma; Carcinoma, Ovarian Epithelial; Neoplasms; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Verrucous; Salivary Gland Neoplasms; Nose Neoplasms; Colonic Neopla | Details |
| Bevacizumab biosimilar(Dr. Reddy's Laboratories) | DRL-BZ | Approved | Dr.Reddy's Laboratories Ltd | Versavo, Persivia | India | Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Glioblastoma; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell | Dr.Reddy's Laboratories Ltd | 2019-08-19 | Ovarian Neoplasms; Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Celltrion) | CTP-16; CT-16; CT-P16 | Approved | Celltrion Inc | Vegzelma | EU | Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Carcinoma, Renal Cell | Celltrion Healthcare Hungary Kft | 2022-08-17 | Ovarian Neoplasms; Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Approved | Momenta, Mylan Nv | YESAFILI | EU | Myopia, Degenerative; Diabetic Retinopathy; Retinal Vein Occlusion; Diabetes Complications; Macular Edema | Viatris Ltd | 2023-09-15 | Macular Edema; Myopia, Degenerative; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Complications; Diabetic Retinopathy; Retinal Vein Occlusion | Details |
| Ranibizumab biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Razumab | India | Macular Degeneration | Intas Biopharmaceuticals | 2015-01-01 | Macular Degeneration | Details | |
| Bevacizumab biosimilar (Outlook) | ONS-5010; ONS-1045 | Approved | Outlook Therapeutics Inc | Lytenava | EU | Wet Macular Degeneration | Outlook Therapeutics Ltd, null | 2024-05-27 | Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration; Retinal Vein Occlusion | Details |
| Ranibizumab biosimilar (Xbrane) | Approved | Xbrane Biopharma Ab | Ximluci | EU | Macular Edema; Wet Macular Degeneration; Diabetes Complications; Diabetic Retinopathy | Stada Arzneimittel Ag | 2022-11-09 | Macular Edema; Wet Macular Degeneration; Diabetes Complications; Macular Degeneration; Diabetic Retinopathy | Details | |
| Bevacizumab biosimilar (Boan Biopharma) | LY-01008; BA-1101 | Approved | Shandong Boan Biotechnology Co Ltd | 博优诺, Boyounuo | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Shandong Boan Biotechnology Co Ltd | 2021-05-07 | Glioblastoma; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Shanghai Henlius Biotech) | HLX-04; HLX04-O | Approved | Shanghai Henlius Biotech Inc | 汉贝泰 | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Shanghai Henlius Biopharmaceuticals Co Ltd | 2021-11-30 | Solid tumours; Carcinoma; Rectal Neoplasms; Carcinoma, Ovarian Epithelial; Glioblastoma; Wet Macular Degeneration; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Macular Degeneration; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Biocad) | BCD-021 | Approved | BIOCAD JSC | Avegra | Russian Federation | Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Glioblastoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial | BIOCAD JSC | 2015-11-25 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Wet Macular Degeneration; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Macular Degeneration | Details |
| Bevacizumab biosimilar (Sinocelltech) | SCT-510; SCT510A; SCT-510A | Approved | SinoCelltech Ltd | 安贝珠 | Mainland China | Glioblastoma; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | SinoCelltech Ltd | 2023-06-27 | Ovarian Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Wet Macular Degeneration; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Macular Degeneration | Details |
| Ranibizumab biosimilar (Qilu Pharmaceutical) | BCD-300; QL-1205 | Approved | Biocnd, Qilu Pharmaceutical Co Ltd | Rimmyrah | EU | Myopia, Degenerative; Macular Edema; Wet Macular Degeneration; Choroidal Neovascularization; Diabetes Complications | Qilu Pharma Spain Sa | 2024-01-05 | Macular Edema; Myopia, Degenerative; Wet Macular Degeneration; Diabetic macular oedema; Diabetes Complications; Macular Degeneration; Myopia; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetic Retinopathy | Details |
| Bevacizumab biosimilar (Allergan/Amgen) | ABP-215 | Approved | Amgen Inc | Mvasi | United States | Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma | Amgen Inc | 2017-09-14 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Aflibercept biosimilar (Qilu Pharmaceutical) | QL-1207 | Approved | Qilu Pharmaceutical Co Ltd | Mainland China | Macular Degeneration; Diabetic macular oedema | Qilu Pharmaceutical Co Ltd | 2023-12-13 | Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details | |
| Ranibizumab biosimilar (Senju) | GBS-007; OT-701; SJP-0133 | Approved | Senju Pharmaceutical Co Ltd | Japan | Macular Degeneration | Senju Pharmaceutical Co Ltd | 2021-09-27 | Wet Macular Degeneration; Macular Degeneration | Details | |
| Aflibercept biosimilar (Amgen) | ABP-938 | Approved | Amgen Inc | PAVBLU | United States | Diabetic Retinopathy; Macular Edema; Wet Macular Degeneration; Diabetic macular oedema | Amgen Inc | 2024-08-23 | Macular Edema; Wet Macular Degeneration; Vascular Diseases; Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy | Details |
| Bevacizumab biosimilar (mAbixience) | MB02; BEVZ-92; BEVZ92-MB02; AP-01 | Approved | Mabxience Sa | Alymsys | Argentina | Colorectal Neoplasms; Carcinoma, Renal Cell; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Stada Arzneimittel Ag | 2013-10-25 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Neovasculgen | PI-VEGF165 | Approved | Human Stem Cells Institute | Neovasculgen | Russian Federation | Peripheral Arterial Disease | Human Stem Cells Institute | 2011-12-07 | Peripheral Arterial Disease; Peripheral Nerve Injuries | Details |
| Nivolumab/Hyaluronidase | ONO-4538HSC | Approved | Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd | OPDIVO QVANTIG, Opdivo Qvantig | United States | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Hepatocellular | Bristol-Myers Squibb Company | 2024-12-27 | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular | Details |
| Bevacizumab biosimilar (CTTQ Pharma) | TQ-B2302 | Approved | 安倍斯 | Mainland China | Glioblastoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-02-28 | Ovarian Neoplasms; Rectal Neoplasms; Glioblastoma; Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details | |
| Bevacizumab biosimilar (Biocon/Mylan) | MYL-1402O | Approved | Biocon Ltd | Lextemy, KRABEVA, Abevmy | India | Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Ovarian Neoplasms; Brain Neoplasms | Mylan Pharmaceuticals Private Ltd | 2017-11-27 | Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Brain Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Conbercept | FP-3; KH-902 | Approved | Chengdu Kanghong Biotechnologies Co Ltd | 朗沐, Langmu | Mainland China | Macular Degeneration | Chengdu Kanghong Biotechnologies Co Ltd | 2013-11-27 | Vision Disorders; Macular Edema; Diabetic macular oedema; Wet Macular Degeneration; Hemangioma; Retinoblastoma; Uveitis; Macular Degeneration; Diabetes Mellitus; Corneal Neovascularization; Retinal Vein Occlusion; Choroidal Neovascularization | Details |
| Bevacizumab biosimilar(Apotex ) | Approved | Apotex Inc | BAMBEVI | Canada | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Glioblastoma | Apotex Inc | 2021-09-23 | Carcinoma, Ovarian Epithelial; Glioblastoma; Colorectal Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Aflibercept | BAY-865321; BAT-86-5321 | Approved | Regeneron Pharmaceuticals Inc, Bayer AG | Eylea, 艾力雅 | United States | Macular Degeneration; Macular Edema | Regeneron Pharmaceuticals Inc | 2011-11-18 | Wet Macular Degeneration; Corneal Neovascularization; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Retinopathy of Prematurity; Choroidal Neovascularization; Diabetic Retinopathy; Macular Degeneration; Retinal Vein Occlusion; Lymphoma, Non-Hodgkin; Retinal Degeneration; Eye Diseases; Vitreous Hemorrhage; Diabetes Complications; Colorectal Neoplasms; Prostatic Neoplasms; Drug-Related Side Effects and Adverse Reactions; Diabetic macular oedema; Retinitis Pigmentosa; Multiple Myeloma; Myopia, Degenerative; Retinal Diseases; Central Serous Chorioretinopathy; Colonic Neoplasms; Neoplasms; Rectal Neoplasms; Diabetes Mellitus, Type 2; Choroid Diseases; Glaucoma, Neovascular; Macular Edema; Cataract; Diabetes Mellitus, Type 1 | Details |
| Bevacizumab biosimilar (Jiangsu Hengrui Medicine) | BP-102 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妥 | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2021-06-22 | Solid tumours; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Aflibercept biosimilar (HEXAL/Sandoz) | SOK-583A1; SOK583A1; SOK-583 | Approved | Sandoz, Hexal | ENZEEVU, Afqlir | United States | Wet Macular Degeneration | Sandoz Inc | 2024-08-09 | Macular Edema; Retinal Diseases; Wet Macular Degeneration; Diabetes Complications; Retinal Vein Occlusion; Macular Degeneration | Details |
| Aflibercept biosimilar (Celltrion) | CT-P42 | Approved | Celltrion Inc | Eydenzelt | South Korea | Wet Macular Degeneration; Diabetic macular oedema | Celltrion Inc | 2024-05-30 | Diabetic macular oedema; Wet Macular Degeneration; Choroidal Neovascularization; Retinal Vein Occlusion | Details |
| Ziv-aflibercept | BAY-865321; AVE-0005 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Zaltrap | United States | Colorectal Neoplasms | Sanofi-Aventis U.S. Llc | 2012-08-03 | Endometrial Neoplasms; Urethral Neoplasms; Breast Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Ureteral Neoplasms; Genital Neoplasms, Female; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Astrocytoma; Gliosarcoma; Lung Neoplasms; Lymphoma; Metastatic breast cancer; Prostatic Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Glioma; Carcinoma, Neuroendocrine; Uterine Neoplasms; Fallopian Tube Neoplasms; Retinal Vein Occlusion; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma; Small Cell Lung Carcinoma; Skin Melanoma; Leukemia; Solid tumours; Multiple Endocrine Neoplasia Type 1; Leiomyosarcoma; Rectal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Papillary; Ovarian Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Carcinoma, Ovarian Epithelial; L | Details |
| Ranibizumab | RG-3645; rhu-Fab-VEG; AMD-rhuFab-V2; AMD-Fab; rhuFab-V2; Y-0317; RFB-002; RG-6321 | Approved | Novartis Pharma Ag, Genentech Inc | Lucentis, 诺适得, Susvimo | United States | Macular Degeneration | Genentech Inc | 2006-06-30 | Retinal Degeneration; Hemangioma; Retinoblastoma; Vascular Diseases; Retinal Detachment; Pseudoxanthoma Elasticum; Retinal Neovascularization; Cardiovascular Diseases; Diabetes Complications; Macular telangiectasia; Ischemia; Uveitis; Vitreous Hemorrhage; Eye Diseases; Glaucoma; Choroidal Neovascularization; Retinal Vein Occlusion; Diabetes Mellitus; Macular Degeneration; Diabetic Retinopathy; Myopia; Corneal Neovascularization; von Hippel-Lindau Disease; Conjunctival Neoplasms; Retinopathy of Prematurity; Port-Wine Stain; Melanoma; Macular telangiectasia 2; Strongyloidiasis; Optic Neuropathy, Ischemic; Polypoidal choroidal vasculopathy; Pterygium; Epistaxis; Telangiectasia, Hereditary Hemorrhagic; Retinal Telangiectasis; Cataract; Diabetic Angiopathies; Iris Diseases; Macular Edema; Depression; Telangiectasis; Vision Disorders; Vitreous Detachment; Glaucoma, Neovascular; Neovascularization, Pathologic; Central Serous Chorioretinopathy; Histoplasmosis; Myopia, Degenerative; Pathologic Processes; Retinal Disea | Details |
| Aflibercept biosimilar (Bioeq) | FYB-203 | Approved | Formycon AG | AHZANTIVE, Baiama | United States | Diabetic Retinopathy; Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Retinal Vein Occlusion; Macular Degeneration | Formycon AG | 2024-06-28 | Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Diabetes Complications; Retinal Vein Occlusion; Macular Degeneration; Diabetic Retinopathy; Choroidal Neovascularization | Details |
| Aflibercept biosimilar (Samsung Bioepis) | SB-15; AM003; SB15 | Approved | Samsung Bioepis Co Ltd | OPUVIZ, Opuviz, AFILIVU | United States | Diabetic macular oedema; Macular Edema; Wet Macular Degeneration; Diabetic Retinopathy | Samsung Bioepis Co Ltd | 2024-05-20 | Macular Edema; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Complications; Macular Degeneration; Retinal Vein Occlusion; Diabetic Retinopathy | Details |
| Bevacizumab biosimilar (Reliance Life Sciences) | R-TPR-023 | Approved | Reliance Life Sciences | BevaciRel | India | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Carcinoma, Renal Cell; Uterine Cervical Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms | Reliance Life Sciences | 2016-06-13 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Hualan Biological Engineering) | WBP-264 | Approved | Hualan Genetic Engineering Co Ltd | Mainland China | Peritoneal Neoplasms; Uterine Cervical Neoplasms; Colorectal Neoplasms; Glioblastoma; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung | Hualan Genetic Engineering Co Ltd | 2024-11-15 | Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details | |
| Faricimab | RO-6867461; RG-7716 | Approved | F. Hoffmann-La Roche Ltd, Genentech Inc | Vabysmo, 罗视佳 | United States | Wet Macular Degeneration; Diabetic macular oedema | Genentech Inc | 2022-01-28 | Polypoidal choroidal vasculopathy; Choroid Diseases; Macular Edema; Vision Disorders; Retinal Diseases; Wet Macular Degeneration; Diabetic macular oedema; Diabetes Complications; Choroidal Neovascularization; Myopia; Retinal Vein Occlusion; Macular Degeneration; Diabetes Mellitus; Diabetic Retinopathy | Details |
| Ivonescimab | AK-112; SMT-112 | Approved | Zhongshan Akeso Biopharma Co Ltd | 依达方 | Mainland China | Carcinoma, Non-Small-Cell Lung | Akeso-Sino Pharma Co Ltd | 2024-05-24 | Brain metastases; Adrenocortical Carcinoma; Mesothelioma; Paget Disease, Extramammary; Prostatic Neoplasms; Sarcoma; Breast Neoplasms; Genital Neoplasms, Female; Colorectal Neoplasms; Bile Duct Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Adenoid Cystic; Penile Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Paraganglioma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Angiomyolipoma; Uterine Cervical Neoplasms; Stomach Neoplasms; Ovarian Neoplasms; Kidney Neoplasms; Rhabdomyosarcoma; Pheochromocytoma; Urachal Cyst; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Solid tumours; Esophageal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Salivary Gland Neoplasms; Carcinoma, Transitional Cell; Perivascular Epithelioid Cell Neoplasms; Glioblastoma; Pancreatic Neoplasms | Details |
| Bevacizumab biosimilar (Hetero Drugs) | Approved | Hetero Drugs Ltd | Cizumab | India | Colorectal Neoplasms | Hetero Drugs Ltd | 2016-06-27 | Colorectal Neoplasms | Details | |
| Bevacizumab biosimilar (Bio-Thera Solutions) | BAT-1706; GP-2019 | Approved | Bio-Thera Solutions Ltd | 普贝希, AVZIVI | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Bio-Thera Solutions Ltd, BeOne Medicines Ltd | 2021-11-17 | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Betta/Mabworks) | MIL-60 | Approved | Institute Of Basic Medicine, Chinese Academy Of Medical Sciences, Beijing Mabworks Biotech Co Ltd | 贝安汀 | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2021-11-24 | Carcinoma, Ovarian Epithelial; Glioblastoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
- Molekülinformation
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main